These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30546433)

  • 1. Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report.
    Xia Y; Tian X; Wang J; Qiao D; Liu X; Xiao L; Liang W; Ban D; Chu J; Yu J; Wang R; Tian G; Wang M
    Oncol Lett; 2018 Dec; 16(6):6998-7007. PubMed ID: 30546433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine-2,3-dioxygenase in microenvironment of nonsmall cell lung cancer.
    Wang H; Xia Y; Yu J; Guan H; Wu Z; Ban D; Wang M
    HLA; 2019 Jul; 94(1):39-48. PubMed ID: 30953385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
    Stadtmauer EA; Faitg TH; Lowther DE; Badros AZ; Chagin K; Dengel K; Iyengar M; Melchiori L; Navenot JM; Norry E; Trivedi T; Wang R; Binder GK; Amado R; Rapoport AP
    Blood Adv; 2019 Jul; 3(13):2022-2034. PubMed ID: 31289029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of NY-ESO-1
    Zhang H; Sun M; Wang J; Zeng B; Cao X; Han Y; Tan S; Gao GF
    Front Immunol; 2021; 12():644520. PubMed ID: 33833762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
    Ishihara M; Nishida Y; Kitano S; Kawai A; Muraoka D; Momose F; Harada N; Miyahara Y; Seo N; Hattori H; Takada K; Emori M; Kakunaga S; Endo M; Matsumoto Y; Sasada T; Sato E; Yamada T; Matsumine A; Nagata Y; Watanabe T; Kageyama S; Shiku H
    Int J Cancer; 2023 Jun; 152(12):2554-2566. PubMed ID: 36727538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rare population of tumor antigen-specific CD4
    Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
    J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
    Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
    Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
    Ishihara M; Kitano S; Kageyama S; Miyahara Y; Yamamoto N; Kato H; Mishima H; Hattori H; Funakoshi T; Kojima T; Sasada T; Sato E; Okamoto S; Tomura D; Nukaya I; Chono H; Mineno J; Kairi MF; Diem Hoang Nguyen P; Simoni Y; Nardin A; Newell E; Fehlings M; Ikeda H; Watanabe T; Shiku H
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35768164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma.
    Pan Q; Weng D; Liu J; Han Z; Ou Y; Xu B; Peng R; Que Y; Wen X; Yang J; Zhong S; Zeng L; Chen A; Gong H; Lin Y; Chen J; Ma K; Lau JYN; Li Y; Fan Z; Zhang X
    Cell Rep Med; 2023 Aug; 4(8):101133. PubMed ID: 37586317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.
    Merhi M; Raza A; Inchakalody VP; Siveen KS; Kumar D; Sahir F; Mestiri S; Hydrose S; Allahverdi N; Jalis M; Relecom A; Al Zaidan L; Hamid MSE; Mostafa M; Gul ARZ; Uddin S; Al Homsi M; Dermime S
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32913031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study.
    Safarzadeh Kozani P; Shokrgozar MA; Evazalipour M; Roudkenar MH
    Int Immunopharmacol; 2022 Sep; 110():109055. PubMed ID: 35853277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.
    Bethune MT; Li XH; Yu J; McLaughlin J; Cheng D; Mathis C; Moreno BH; Woods K; Knights AJ; Garcia-Diaz A; Wong S; Hu-Lieskovan S; Puig-Saus C; Cebon J; Ribas A; Yang L; Witte ON; Baltimore D
    Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10702-E10711. PubMed ID: 30348802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
    Puig-Saus C; Parisi G; Garcia-Diaz A; Krystofinski PE; Sandoval S; Zhang R; Champhekar AS; McCabe J; Cheung-Lau GC; Truong NA; Vega-Crespo A; Komenan MDS; Pang J; Macabali MH; Saco JD; Goodwin JL; Bolon B; Seet CS; Montel-Hagen A; Crooks GM; Hollis RP; Campo-Fernandez B; Bischof D; Cornetta K; Gschweng EH; Adelson C; Nguyen A; Yang L; Witte ON; Baltimore D; Comin-Anduix B; Kohn DB; Wang X; Cabrera P; Kaplan-Lefko PJ; Berent-Maoz B; Ribas A
    Clin Cancer Res; 2019 Feb; 25(3):1000-1011. PubMed ID: 30409823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route.
    Amissah OB; Chen W; de Dieu Habimana J; Sun Y; Lin L; Liu Y; Wang L; Liu Z; Mukama O; Basnet R; Liu H; Li J; Ding X; Lv L; Chen M; Liang Y; Huang R; Li Z
    Cancer Cell Int; 2024 Feb; 24(1):64. PubMed ID: 38336680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability.
    Yu G; Wang W; He X; Xu J; Xu R; Wan T; Wu Y
    Front Oncol; 2022; 12():895103. PubMed ID: 35774131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
    Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
    Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
    Krönig H; Hofer K; Conrad H; Guilaume P; Müller J; Schiemann M; Lennerz V; Cosma A; Peschel C; Busch DH; Romero P; Bernhard H
    Int J Cancer; 2009 Aug; 125(3):649-55. PubMed ID: 19444908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.
    Zhao Y; Zheng Z; Robbins PF; Khong HT; Rosenberg SA; Morgan RA
    J Immunol; 2005 Apr; 174(7):4415-23. PubMed ID: 15778407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
    Poncette L; Chen X; Lorenz FK; Blankenstein T
    J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histological Assessment of Synovial Sarcoma Before and After TCR-T Cell Therapy and Cryoablation: A Case Report.
    Asanuma K; Ishihara M; Nakamura T; Uchida K; Hagi T; Kageyama S; Shiku H; Sudo A
    Anticancer Res; 2023 Dec; 43(12):5737-5748. PubMed ID: 38030212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.